RECURRENT CHILDHOOD OSTEOSARCOMA
Clinical trials for RECURRENT CHILDHOOD OSTEOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHILDHOOD OSTEOSARCOMA trials appear
Sign up with your email to follow new studies for RECURRENT CHILDHOOD OSTEOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: targeted drug shows promise in Gene-Matched tumors
Disease control OngoingThis study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …
Matched conditions: RECURRENT CHILDHOOD OSTEOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on childhood cancers that Won't quit
Disease control TerminatedThis phase 1 trial is testing a new treatment called GD2CART for children and young adults with osteosarcoma or neuroblastoma that has returned or does not respond to standard treatments. GD2CART is made by taking a patient's own T cells (a type of immune cell), adding a new gene…
Matched conditions: RECURRENT CHILDHOOD OSTEOSARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC